We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Photodynamic Therapy With or Without Intravitreal Triamcinolone Acetonide for Symptomatic Polypoidal Choroidal Vasculopathy.
- Authors
Lai, Timothy Y. Y.; Lam, Carol P. S.; Luk, Fiona O. J.; Chan, Rose P. S.; Chan, Wai-Man; Liu, David T. L.; Lam, Dennis S. C.
- Abstract
Purpose: To evaluate the outcome of verteporfin photodynamic therapy (PDT) with or without intravitreal triamcinolone acetonide (IVTA) for the treatment of symptomatic polypoidal choroidal vasculopathy (PCV). Methods: Retrospective analysis of PCV patients who underwent PDT with or without IVTA with follow-up of 2 or more years. Changes in best-corrected visual acuity (BCVA), proportion of eyes with moderate visual loss (3 or more lines), and complications were compared between patients with or without IVTA. Results: Twenty-seven eyes of 27 patients were analyzed, with 12 eyes treated by PDT monotherapy and 15 eyes treated by combined PDT with IVTA. The baseline characteristics of both groups were similar. At 1 year, the mean logMAR BCVA for the PDT monotherapy group improved from 0.74 to 0.58 ( P = 0.011), whereas the combined PDT and IVTA group improved from 0.84 to 0.74 ( P = 0.17). At 2 years, the mean logMAR BCVA for the monotherapy and combined treatment groups were 0.62 and 0.84, respectively, and the changes compared with baseline were not statistically significant. No significant difference was found in the mean logMAR BCVA, the mean line of visual changes, and the mean number of PDT treatments between the 2 groups at 1 and 2 years. One (8.3%) and 4 (26.7%) eyes in the monotherapy and the combined groups lost 3 or more lines at 2 years, respectively. Patients who had combined PDT with IVTA were more likely to develop cataract requiring surgery and ocular hypertension ( P = 0.043 and 0.046, respectively). Conclusions: PDT reduced the risks of visual loss in patients with symptomatic PCV in the short term but the effect might not be sustained after 1 year. The adjunctive use of IVTA during PDT did not appear to result in additional benefit for treating PCV.
- Subjects
PHOTOCHEMOTHERAPY; TRIAMCINOLONE acetonide; VISUAL acuity; CATARACT surgery; BRONCHODILATOR agents
- Publication
Journal of Ocular Pharmacology & Therapeutics, 2010, Vol 26, Issue 1, p91
- ISSN
1080-7683
- Publication type
Article
- DOI
10.1089/jop.2009.0073